November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma
Jun 18, 2023, 16:32

FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma

In a post by on Linkedin, it says, “I’m excited to share that the FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma(DLBCL). Despite the progress we’ve seen in treating DLBCL, additional treatment options are critical for those who relapse or are refractory to other treatments given the aggressive nature of this disease.
Today marks another great advancement for the blood cancer community and reinforces our steadfast commitment to those living with difficult-to-treat cancers.”

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Source: